Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Impact of RAS Mutations in Circulating Tumor DNA for Efficacy of Anti-EGFR Reintroduction Treatment in Patients With Metastatic Colorectal Cancer

NCT03259009 is registered in ClinicalTrials.gov with Association des Gastroentérologues Oncologues as lead sponsor.

NCT NCT03259009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03259009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Impact of RAS Mutations in Circulating Tumor DNA for Efficacy of Anti-EGFR Reintroduction Treatment in Patients With Metastatic Colorectal Cancer
Lead sponsor
Association des Gastroentérologues Oncologues
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2017
Completion date
June 1, 2020
Enrollment
73 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer